Background: Statins reduce the risk of cardiovascular disease in patients with diabetes. This study examined the prevalence of statin use and assessed longterm adherence and persistence among people aged ≥65 years with diabetes. Methods: Pharmaceutical Benefits Scheme data covering a 10% random sample of the Australian population were analyzed. Among older adults with diabetes, the yearly prevalence of statin use was compared via Poisson regression modeling using 2006 as the reference year. A cohort of 7400 new statin users (mean age 72.9 years; 46.2% female) was followed longitudinally. Adherence was assessed via the proportion of days covered (PDC). Statin discontinuation was defined as the first ≥90 days without statin coverage. Results: The prevalence of statin use increased from 52.0% in 2006 to 71.2% in 2016 (age and sex-adjusted rate ratio 1.37; 95% confidence interval 1.33-1.41). No gender differences in statin use were observed, but the likelihood of being dispensed statin decreased with increasing age. Among the longitudinal cohort, the proportion adherent (PDC ≥0.80) decreased from 54.0% at 6 months to 37.0% at 9 years. Over a mean follow-up of 4.9 years, 66.8% discontinued, and the likelihood of stopping statin medication within the first year was 42.7%. No age or gender differences in statin discontinuation were evident. Conclusions: Statin use has increased among older adults with diabetes. However, adherence is low and discontinuation is high. Further investigations into the factors associated with non-adherence or discontinuation of statins are important so as to optimize statin use towards achieving the intended cardiovascular benefits among older people with diabetes.
Introduction
Type 2 diabetes mellitus is prevalent among older people due to a number of factors, including increasing insulin resistance and pancreatic β-cell dysfunction. 1 In the US, over 25% of older adults have diabetes, 2 and in Australia approximately half of those with diabetes are aged ≥65 years. 3 People with diabetes are at high absolute risk of cardiovascular disease (CVD), and experience a high prevalence of comorbidities such as dyslipidemia. 4, 5 Statins have been shown to reduce the risk of atherosclerotic CVD. 6, 7 Thus, many people with diabetes benefit from statin therapy. The current American College of Cardiology/American Heart Association Guidelines recommend early and aggressive use of statins for lipid control among people with diabetes, with treatment targets informed by randomized clinical trials (RCTs). 8, 9 Within Australia, guidelines emphasize that cholesterol treatment should be an integral component of management goals for patients with diabetes while noting that initiation of statin should also be informed by the assessment of absolute cardiovascular risk. 10 However, compliance with clinical practice guidelines is often poor and statin prescribing for patients with diabetes has been shown in some studies to be suboptimal. 11 The benefits of statin therapy accrue over time, 12 and optimal patient adherence is necessary. 13, 14 However, older adults with diabetes may find adherence to statin therapy challenging due to many reasons, including polypharmacy, 15 increased susceptibility to adverse events, 16 and as a result of declining executive and cognitive functioning. 17 There is strong evidence linking statins with increased risk of diabetes. 18 Furthermore, among people with established diabetes, statin therapy has been associated with poor glycemic control, 19 which could contribute to increased discontinuation or poor adherence.
To date, limited studies have examined the patterns of long-term statin adherence and persistence among older adults with diabetes. Given the clinical importance of CVD prevention among patients with diabetes, understanding the dynamics of statin use is important to inform clinical practice. Therefore, in the present study we sought to assess the prevalence of statin use and determine long-term adherence and persistence among people aged ≥65 years with diabetes.
Methods

Study design and data sources
We undertook a retrospective study using data from the Pharmaceutical Benefits Scheme (PBS) covering a random 10% sample of the Australian population. 20 The PBS is funded by the Australian Government and makes prescription medications available to Australians at subsidized costs. Information regarding medications dispensed (item number, name, quantity and date of dispensing), demographic information (sex, year of birth, and year of death, if applicable), people's concessional status, prescriber information (identification number and specialty area), and the state or territory of the pharmacy is contained in PBS data. The PBS datasets do not include diagnosis information or laboratory test results (such as HbA1c). The datasets were de-identified using unique identifiers for each person. For those who died, only year of death is captured in the dataset. Thus, for the purposes of our analyses, we considered the month of death to be the month following that person's last dispensing of any medication in the dataset.
Statins were identified using the World Health Organization's (WHO) Anatomical Therapeutic Chemical (ATC) system codes C10AA, C10BA, C10BX (see Table S1 , available as Supplementary Material to this paper). 21 The statins included were fluvastatin, pravastatin, simvastatin, atorvastatin, and rosuvastatin. Both plain and combination products were included. Cerivastatin was not included in the present study because it was withdrawn from the Australian market in 2001; 22 pitavastatin was not included either because it is not listed on the PBS. 23 Lovastatin is not available in Australia. The statins were grouped according to intensity based on their capacity to lower low-density lipoprotein cholesterol (LDL-C) levels. As per their daily doses, statins that reduce LDL-C by <30%, 30%-<50% and ≥ 50% were categorized as low, moderate and high intensity, respectively (Table S2) . 9, 24 
Study population
This study was performed among adults aged ≥65 years with diabetes who were dispensed medications included in the PBS datasets between 1 January 2007 and 31 December 2016. Because no diagnosis records or laboratory results are available in the PBS datasets, diabetes status was ascertained via medication dispensation information (i.e. any individual being dispensed medications belonging to ATC code A10 was deemed to have diabetes; Table S1 ). In addition, prior to 2012, medications that were priced below the 'general patient copayment threshold' were not captured in the PBS datasets. 25 Therefore, as adopted in previous studies, 25, 26 we restricted our analysis to people with long-term concession status. Long-term concession status was defined by receipt of ≥90% of medications under concession. Previous studies have found that long-term concession individuals constitute more than 65% of all Australians receiving cardiovascular medications.
25-27
Outcomes
The 1-year prevalence of statin use was computed by dividing the number of people with diabetes who redeemed at least one statin prescription during a calendar year by the total number of people with diabetes in that particular year. 28 For the adherence and discontinuation analyses, we included only new statin users, defined as any person with diabetes being dispensed a statin with no statin dispensation in the previous 12 months. In addition, only those who initiated statin treatment between 1 January 2007 and 31 March 2016 were included. The new user cohort was subsequently followed until death or 31 December 2016.
Adherence was assessed via the proportion of days covered (PDC) and calculated by dividing the number of days a person had statin medication on hand by the number of days in the period. 29 We assumed a dosage of one tablet per day because previous studies have demonstrated this to be the most commonly dispensed daily dose of statins. 30 If there were overlapping refills, we assumed that the person would finish the current prescriptions before commencing the refill prescription. The PDC was grouped into three categories, namely <0.20%, 0.20%-0.79% and ≥80%, and patients were classified as non-adherent, partially adherent, and adherent, respectively. 31 We estimated cumulative adherence from 6 months to 9 years.
In Australia, a 30-day supply of statin is typically dispensed. Thus, we considered statin users to have discontinued when 90 or more days elapsed after the estimated end date of a statin dispensing and no refill had been made. 25, 29 The time to discontinuation was determined as the period from the index date to the discontinuation (first 90-day gap) date.
Statistical analysis
Descriptive statistics were used to summarize the characteristics of the study population. The yearly prevalence of statin use was calculated for the overall diabetes population and stratified by age (65-74, 75-84 and ≥85 years) and sex. Relative changes in the prevalence of statin use were determined via Poisson regression modeling using 2006 as the reference year. Age-and sex-adjusted rate ratios (aRRs) and corresponding 95% confidence intervals (CIs) are reported for the overall prevalence of statin use. We compared statin use per gender by adjusting for age while differences across age were adjusted for sex. The likelihood of statin discontinuation was assessed by a competing risk proportional hazards regression model, death being the competing risk. 32 The variables included in the model were age, gender, statin type, statin intensity, prescriber type (general practitioner [GP] or other), and year of initiation.
In a sensitivity analyses, we varied the study population by relaxing the criteria to include all people who received ≥80% of medications under concession to assess the robustness of the prevalence estimates. The gap used in the discontinuation analyses was also varied to 45 and 180 days. Statistical analyses were performed using Stata/IC v14.1 (StataCorp, College Station, TX, USA).
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Results
In all, 175 526 long-term concession older adults in the 10% random PBS datasets were dispensed medications for diabetes in the period 2006-2016. The yearly number of people with diabetes more than doubled from 9977 in 2006 to 22 618 in 2016 (Table 1 ). There were more females than males overall, although since 2010 the gender distribution has been even. The mean age remained generally stable across the years.
The prevalence of statin use increased consistently each year from 52.0% in 2006 to 71.2% in 2016 (aRR 1.37; 95% CI 1.33-1.41). There was no gender difference in statin use (aRR for men vs women 0.99; 95% CI 0.98-1.00). The likelihood of being dispensed statins decreased with age (sex-adjusted RR for 75-84 and ≥85 years vs 65-74 years 0.97 [95% CI 0.96-0.98] and 0.77 [95% CI 0.75-0.78], respectively). The overall patterns in the prevalence of statin use did not change when the study population was modified to include all people with diabetes who received ≥80% of medications under concession (Fig. S1) .
Among the older adults with diabetes who were prescribed statins, a cohort of 7400 people who started statin treatment between January 2007 and March 2016 was assembled for the longitudinal analyses. The mean (AESD) age of this cohort was 72.9 AE6.6 years, and 46.2% were women. Of the cohort, 47.5% were initiated by GPs. In addition, 3.4%, 70.2%, and 26.4% commenced with low-, moderate-and high-intensity statins, respectively. By individual statin, 12.5%, 2.2%, 47.75, Unless indicated otherwise, data are given as the mean AE SD or as percentages.
ARR, age-and sex-adjusted rate ratio; CI, confidence interval.
and 37.6% were initiated on simvastatin, atorvastatin, rosuvastatin, or other (fluvastatin or pravastatin), respectively. The mean (AESD) follow-up period for the cohort was 4.9 AE2.7 years, and 18.7% (n = 1382) of the cohort died by the end of the study period. The mean (AESD) PDC decreased from 0.69 AE0.32 at 6 months to 0.56 AE0.31 at 9 years. The proportion of statin users who were adherent (PDC ≥ 0.80) declined from 54.0% at 6 months to 30.7% at 9 years. Conversely, the proportion of patients with very low PDC (<0.20) increased from 16.8% at 6 months to 19.7% at 9 years (Fig. 1) .
Of the new statin users, more than two-thirds (66.8%; n = 4942) discontinued during the follow-up based on the 90-day gap criteria. The overall discontinuation rate was 29.1 per 100 person-years. The likelihood of stopping statin medication at 6 months, 1 year, and 2 years was 27.2%, 42.7%, and 54.1%, respectively (Fig. 2) The proportion of patients that discontinued when 45 and 180 permissible days were applied was 79.4% (n = 5873) and 40.4% (n = 4044), respectively. For the 45-day gap, the overall discontinuation rate was 47.5 per 100 person-years, and likelihood of stopping statin medication was 41.0%, 55.8%, and 66.8% at 6 months, 1 year, and 2 years, respectively. With a 180-day permissible gap, the overall discontinuation rate was 18.7 per 100 person-years, and the likelihood of statin discontinuation at 1 year and 2 years was 28.3% and 41.5%, respectively.
Discussion
We found increased use of statins among older adults with diabetes over the past decade. Compared with 2007, older Australians with diabetes in 2016 were 37% more likely to be dispensed statins. These trends are consistent with the patterns of statin use reported among cohorts of patients with diabetes in other developed countries, 33 and among general populations of older adults. 34, 35 For people with diabetes who are at increased risk of CVD, guidelines have increasingly emphasized the importance of statin treatment. 8, 9, 36 In particular, current clinical guidelines recommend statins for all patients with diabetes aged ≥40 years, with or without CVD. 8 However, despite the increase observed, nearly 30% of older Australians with diabetes were not prescribed statins in 2016, and this warrants further investigation to identify contributory factors so as to optimize statin use in this population at high risk of CVD progression and death. 37 Statin use was lower among people aged ≥75 years, which may largely reflect the growing concern or debate around the benefits and harms of statin therapy in this population. 38 We observed poor statin adherence among older people with diabetes. The proportion of people who were adherent declined sharply within the first 6 months, before reaching a slower rate of decline over time. This observation is consistent with data from other longitudinal studies. 39 In a recent meta-analysis that pooled data from more than 3 million older statin users from over 40 countries, it was noted that the proportion adherent (PDC/medication possession ratio ≥ 0.80) declined from 60% at 6 months to just 28% at 10 years. 40 These patterns highlight the need for support with adherence at commencement of treatment and for a longer period as part of regular medication management plans. 41 The need for increased efforts at improving adherence is further supported by increasing evidence of adverse clinical outcomes as a consequence of poor adherence. For example, compared with patients with diabetes who are adherent to statin therapy, those who are non-adherent are approximately 1.2-to 5.3-fold more likely to develop CVD and 1.3-to 3.5-fold more likely to die from it.
42
Our analysis also showed that among older Australians with diabetes who commenced statin therapy, more than 66% discontinued, including over 40% who did so within the first treatment year. This discontinuation is comparable to previously reported rates in the Netherlands. 43 However, some studies of older populations have reported slightly different statin persistence rates, a trend that is often attributed to the permissible gap applied and the length of follow-up. 44 For example, Abughosh et al. 45 reported a statin discontinuation rate of 39.0% among older Americans when applying a permissible gap of 180 days, whereas a discontinuation rate of >80% was reported for Italian patients based on a permissible gap of 30 days. 46 Indeed, our sensitivity analyses showed that the level of discontinuation was dictated by the permissible gap applied, suggesting that the use of shorter gaps may lead to overestimation of discontinuation rates. Regardless, the overall discontinuation is high, which needs to be addressed because evidence suggests that statin cessation in patients with diabetes is associated with adverse clinical outcomes. For example, 79% of people with diabetes who had stopped statin treatment after having achieved LDL-C targets experienced relapsed dyslipidemia compared with 3% of those who maintained treatment. 47 People with diabetes who discontinue statins are also up to fivefold more likely to die than those persisting with treatment. 42 We also found that people who were initiated on statins by GPs were approximately 13% more likely to discontinue than those initiated by others, including specialists. Although we had no clinical data for our analyses, we speculate that this trend is likely the result of patients initiated by non-GPs being higher-risk patients, who may perceive grater gains from statin therapy and may be more committed to treatment. 25, 40 Our results reiterate the need for interventions to improve statin adherence and persistence among older people with diabetes for whom statins are deemed to be clinically essential. A recent study suggested that realtime medication monitoring that is combined with short message service (SMS) reminders was effective at improving refill adherence among patients with diabetes. 48 Due to the likelihood of polypharmacy among older people, 15 measures to reduce regimen complexity are also necessary. 49 Furthermore, interventions that Figure 2 Cumulative incidence function curve of the probability of discontinuing statin therapy in a cohort of older adults with diabetes in which stopping was defined as 45, 90, and 180 or more days without statin medication.
seek to improve patient education or offer extended supervisory health services 50 have been noted to enhance compliance, with the best outcomes likely to be achieved by a combination of multifaceted interventions. 41, 51 The present study has important strengths and limitations. To our knowledge, this is the first study to describe in detail statin use and long-term adherence and discontinuation patterns among older adults with diabetes in Australia. Our analysis was based on a large sample of data from the PBS, which has been considered to be reliable for pharmaceutical policy and health services research in Australia. 20 A main limitation of the present study is that we had no information on the underlying reasons as to why patients were non-adherent or discontinued statins. It is possible that some discontinuation may have been due to adverse events or directed by clinicians. Furthermore, given that we did not have access to hospitalization records, we may have overestimated the treatment gap or underestimated adherence among people who were hospitalized during the follow-up. In addition, our analysis was based only on medication acquisition data, and hence we were unable to verify whether people actually took the statin medications. The present study population was also selected on the basis of diabetes medication use and we may have excluded any people with diabetes being managed with diet alone. We were also unable to stratify our results by the presence or absence of symptomatic cardiovascular events, which may be associated with different patterns of statin use and adherence or persistence. 40 Finally, we did not investigate whether specific statins or intensity were associated with higher or lower rates of adherence or persistence, or sociodemographic or lifestyle factors. However, a recent meta-analysis involving more than 1.8 million older statin users in 13 countries found no significant difference in adherence or persistence according to statin type or intensity. 52 
Conclusions
The proportion of older adults with diabetes using statins has increased over the past decade. However, adherence is poor and discontinuation is high. Further investigations into the factors associated with nonadherence or discontinuation are important so as to optimize statin use to achieve the intended cardiovascular benefits among older people with diabetes. Table S1 . Anatomical Therapeutic Chemical (ATC) classification system codes used to identify people with diabetes and statin scripts. Table S2 . Classification of statins according to intensity. Figure S1 . Trends in the prevalence of statin use among older adults with diabetes whereby the analysis is restricted to all people who received ≥80% of medications under concession.
